114 related articles for article (PubMed ID: 8869462)
21. Longitudinal analysis of factor VIII inhibitors in a previously untreated mild haemophilia A patient with an Arg593-->Cys substitution.
van den Brink EN; Timmermans SM; Turenhout EA; Bank CM; Fijnvandraat K; Voorberg J; Peters M
Thromb Haemost; 1999 May; 81(5):723-6. PubMed ID: 10365744
[TBL] [Abstract][Full Text] [Related]
22. Factor VIII Ise (R2159C) in a patient with mild hemophilia A, an abnormal factor VIII with retention of function but modification of C2 epitopes.
Suzuki H; Shima M; Arai M; Kagawa K; Fukutake K; Kamisue S; Nakai H; Morichika S; Tanaka I; Inoue M; Gale K; Tuddenham EG; Yoshioka A
Thromb Haemost; 1997 May; 77(5):862-7. PubMed ID: 9184393
[TBL] [Abstract][Full Text] [Related]
23. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor.
Suzuki T; Arai M; Amano K; Kagawa K; Fukutake K
Thromb Haemost; 1996 Nov; 76(5):749-54. PubMed ID: 8950785
[TBL] [Abstract][Full Text] [Related]
24. Role of anti-idiotypic antibodies in immune tolerance induction.
Gilles JG
Haemophilia; 2010 May; 16(102):80-3. PubMed ID: 20536989
[TBL] [Abstract][Full Text] [Related]
25. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile.
Greninger DA; Saint-Remy JM; Jacquemin M; Benhida A; DiMichele DM
Haemophilia; 2008 Mar; 14(2):295-302. PubMed ID: 18081826
[TBL] [Abstract][Full Text] [Related]
26. A soluble recombinant factor VIII fragment containing the A2 domain binds to some human anti-factor VIII antibodies that are not detected by immunoblotting.
Scandella D; Timmons L; Mattingly M; Trabold N; Hoyer LW
Thromb Haemost; 1992 Jun; 67(6):665-71. PubMed ID: 1509407
[TBL] [Abstract][Full Text] [Related]
27. Epitope specificity and inactivation mechanisms of factor VIII inhibitor antibodies.
Scandella D
Vox Sang; 1999; 77 Suppl 1():17-20. PubMed ID: 10529680
[TBL] [Abstract][Full Text] [Related]
28. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model.
Behrmann M; Pasi J; Saint-Remy JM; Kotitschke R; Kloft M
Thromb Haemost; 2002 Aug; 88(2):221-9. PubMed ID: 12195693
[TBL] [Abstract][Full Text] [Related]
29. Restricted epitope specificity of anti-FVIII antibodies that appeared during a recent outbreak of inhibitors.
Gilles JG; Peerlinck K; Arnout J; Vermylen J; Saint-Remy JM
Thromb Haemost; 1997 May; 77(5):938-43. PubMed ID: 9184406
[TBL] [Abstract][Full Text] [Related]
30. Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors.
Astermark J
Haemophilia; 2006 Dec; 12 Suppl 6():8-13; discussion 13-4. PubMed ID: 17123388
[TBL] [Abstract][Full Text] [Related]
31. Identification of plasma antibody epitopes and gene abnormalities in Japanese hemophilia A patients with factor VIII inhibitor.
Sugihara T; Takahashi I; Kojima T; Okamoto Y; Yamamoto K; Kamiya T; Matsushita T; Saito H
Nagoya J Med Sci; 2000 May; 63(1-2):25-39. PubMed ID: 10911718
[TBL] [Abstract][Full Text] [Related]
32. Mapping of natural anti-factor VIII antibodies in plasma pools from healthy donors: use of rationally designed synthetic peptides.
Di Giambattista M; Branckaert T; Laub R
Biologicals; 2001; 29(3-4):229-32. PubMed ID: 11851320
[TBL] [Abstract][Full Text] [Related]
33. A recombinant factor VIII A2 domain polypeptide quantitatively neutralizes human inhibitor antibodies that bind to A2.
Scandella D; Mattingly M; Prescott R
Blood; 1993 Sep; 82(6):1767-75. PubMed ID: 7691236
[TBL] [Abstract][Full Text] [Related]
34. Epitope mapping of inhibitory antibodies targeting the C2 domain of coagulation factor VIII by hydrogen-deuterium exchange mass spectrometry.
Sevy AM; Healey JF; Deng W; Spiegel PC; Meeks SL; Li R
J Thromb Haemost; 2013 Dec; 11(12):2128-36. PubMed ID: 24152306
[TBL] [Abstract][Full Text] [Related]
35. Immunobiology of inhibitor development in hemophilia A.
Fijnvandraat K; Bril WS; Voorberg J
Semin Thromb Hemost; 2003 Feb; 29(1):61-8. PubMed ID: 12640567
[TBL] [Abstract][Full Text] [Related]
36. Anti-factor VIII antibodies: a 2005 update.
Lavigne-Lissalde G; Schved JF; Granier C; Villard S
Thromb Haemost; 2005 Oct; 94(4):760-9. PubMed ID: 16270627
[TBL] [Abstract][Full Text] [Related]
37. High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors.
Batsuli G; Deng W; Healey JF; Parker ET; Baldwin WH; Cox C; Nguyen B; Kahle J; Königs C; Li R; Lollar P; Meeks SL
Blood; 2016 Oct; 128(16):2055-2067. PubMed ID: 27381905
[TBL] [Abstract][Full Text] [Related]
38. Epitope localization of anti-factor VIII monoclonal antibodies determined by recombinant peptides.
Ware J; Toomey JR; Stafford DW
Thromb Haemost; 1989 Apr; 61(2):225-9. PubMed ID: 2473538
[TBL] [Abstract][Full Text] [Related]
39. Characterization of antibodies to factor VIII in hemophilia A patients treated by immune tolerance therapy.
Scandella D; Reyes H; Felch M; Sakurai Y
Haematologica; 2000 Oct; 85(10 Suppl):86-8. PubMed ID: 11187882
[TBL] [Abstract][Full Text] [Related]
40. Mild/moderate haemophilia A: new insights into molecular mechanisms and inhibitor development.
d'Oiron R; Pipe SW; Jacquemin M
Haemophilia; 2008 Jul; 14 Suppl 3():138-46. PubMed ID: 18510534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
